In the case of islet transplantation for the treatment of insulin-dependent diabetes, the primary constraint is a shortage of transplantable pancreatic islet material, while the desired product is the capacity to secrete insulin upon exposure to glucose. This evidence concerns the gene INS and type 1 diabetes mellitus.